Stratec (SBS) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
28 Apr, 2026Executive summary
2025 was marked by geopolitical and market uncertainties, impacting supply chains and customer order behavior, but sales remained nearly stable year-over-year with strong double-digit growth in systems in Q4.
Adjusted EBIT margin met guidance at 10.0% for 2025, down from 13.0% in 2024, reflecting lower scale benefits, adverse product mix, and effective cost management.
Significant progress was made in development partnerships, with new programs and numerous upcoming product launches expected to drive growth from 2026 onward.
Dividend proposal remains stable at EUR 0.60 per share, pending AGM approval.
Financial highlights
FY 2025 sales were EUR 250.9 million, down 2.6% year-over-year (1.1% decline at constant currency).
Adjusted EBIT was EUR 25.2 million (10% margin), down from 13% in 2024.
Adjusted EBITDA was EUR 40.6 million (16.2% margin), down 17.4% from 2024.
Adjusted net income dropped 30.6% to EUR 14.2 million; adjusted EPS fell to EUR 1.17.
Free cash flow turned negative at -EUR 17.2 million, down from EUR 32.7 million in FY 2024.
Net financial debt rose to EUR 112 million; net debt/EBITDA ratio increased to 3.3 from 1.9.
Equity ratio stands at 55.7%.
Outlook and guidance
2026 sales expected to grow mid- to high-single digits (constant currency), with growth back-end loaded in H2.
EBIT margin guidance for 2026 is 10%, with efficiency gains offset by higher input costs.
Investment in tangible and intangible assets targeted at 6.5%-8.5% of sales.
2026–2028: 6%-8% annual sales growth expected; 2028–2030: 10%-12% CAGR.
Adjusted EBIT margin targeted at 13% by 2028 and 15% by 2030.
Latest events from Stratec
- Q2 2026 rebound and strong system sales drove improved cash flow and confirmed growth guidance.SBS
Q2 2026 - Q1 2026 sales and margins fell, but cash flow improved; growth targets and ESG goals remain strong.SBS
Corporate presentation - Sales declined in Q1 2026, but strong cash flow and a robust growth pipeline support future targets.SBS
Investor presentation - Sales and margins fell, but free cash flow surged and 2026 guidance was reaffirmed.SBS
Q1 2026 - Recurring revenue dominates as growth resumes in 2025, driven by innovation and M&A focus.SBS
Health Care Conference - Sales down 6.1% Y/Y; margins stable; Q4 rebound expected from new orders and deliveries.SBS
Q3 2024 - Margins and cash flow improved despite lower sales; 2024 guidance remains unchanged.SBS
Q2 2024 - Margin and cash flow gains in 2024; 2025 to see modest growth and margin normalization.SBS
Q4 2024 - Stable margins and recurring revenues support growth as innovation and M&A drive recovery.SBS
43rd Annual J.P. Morgan Healthcare Conference 2025